Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA3 | P0DMS8 | 4/20 | 0.55 |
| ▸ | ADORA2B | P29275 | 4/20 | 0.55 |
| ▸ | ADORA1 | P30542 | 4/20 | 0.55 |
| ▸ | PDE5A | O76074 | 14/20 | 0.43 |
| ▸ | PDE2A | O00408 | 1/20 | 0.40 |
| ▸ | PDE9A | O76083 | 1/20 | 0.40 |
| ▸ | PDE4A | P27815 | 1/20 | 0.40 |
| ▸ | PDE6C | P51160 | 1/20 | 0.40 |
| ▸ | PDE1A | P54750 | 1/20 | 0.40 |
| ▸ | PDE11A | Q9HCR9 | 1/20 | 0.40 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6304647 | 0.92 | ADORA3 (0.55) | ADORA3ADORA2BADORA1PDE5APDE2A | |
| SCHEMBL6304614 | 0.86 | PDE5A (0.46) | ADORA2BPDE5APDE2APDE9APDE4A | |
| SCHEMBL6305668 | 0.83 | PDE5A (0.42) | ADORA2BPDE5A | |
| SCHEMBL5830513 | 0.83 | ADORA3 (0.46) | ADORA3ADORA2BADORA1PDE5A | |
| SCHEMBL6307577 | 0.82 | PDE5A (0.55) | PDE5A | |
| SCHEMBL6305254 | 0.81 | PDE5A (0.51) | ADORA3ADORA2BADORA1PDE5A | |
| SCHEMBL6312898 | 0.80 | ADORA2B (0.66) | ADORA3ADORA2BADORA1PDE5A | |
| SCHEMBL6313061 | 0.77 | PDE5A (0.69) | ADORA1PDE5APDE2APDE9APDE4A | |
| SCHEMBL6313621 | 0.76 | PDE5A (0.56) | PDE5A | |
| SCHEMBL6306646 | 0.76 | PDE5A (0.59) | PDE5A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6943253-B2 | 6-phenylpyrrolopyrimidinedione derivatives | ALMIRALL PRODESFARMA S.A. (ES) | 2005-09-13 | — | — | US | disclosed |
| EP-1286997-B1 | 6-PHENYLPYRROLOPYRIMIDINEDIONE DERIVATIVES | ALMIRALL PRODESFARMA SA (ES) | 2004-08-18 | — | — | EP | disclosed |
| US-20030232838-A1 | Nitrogen compounds such as 3-Methyl-6-(5-(4-methylpiperazine-1-sulphonyl)-2-propoxyphenyl)-1-propyl-1,5-dihydropyrrolo(3,2-d)pyrimidine-2,4-dione, used for prophylaxis of cardiovascular disorders | PARALLEL WIRELESS, INC. | 2003-12-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030232838-A1 | Nitrogen compounds such as 3-Methyl-6-(5-(4-methylpiperazine-1-sulphonyl)-2-propoxyphenyl)-1-propyl-1,5-dihydropyrrolo(3,2-d)pyrimidine-2,4-dione, used for prophylaxis of cardiovascular disorders | PDE5A, PDE2A, PDE3A | ADORA3 605/4885ADORA2B 641/4885ADORA1 679/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.